

BIOCON GROUP

FACT SHEET

Dec - 2023

BIOCON LIMITED (CONSOLIDATED)				
PROFIT & LOSS STATEMENT		(Rs. Crores)		
Particulars	Q3 FY 24	Q3 FY 23	Variance %	
<u>INCOME</u>				
Generics	703	760	-7%	
Biosimilars	2,483	1,507	65%	
Novel Biologics	-	-	0%	
Research services	854	786	9%	
Inter-segment	(86)	(112)	-23%	
Revenue from operations #	3,954	2,941	34%	
Other income	565	79	619%	
TOTAL REVENUE	4,519	3,020	50%	
<u>EXPENDITURE</u>				
Material & Power costs	1,320	1,090	21%	
Staff costs	555	520	7%	
Research & Development expenses*	329	337	-2%	
Other expenses	823	349	136%	
Manufacturing, staff & other expenses	3,027	2,297	32%	
EBITDA	1,492	723	106%	
Interest & Finance charges	267	120	122%	
Depreciation & Amortisation	415	301	38%	
Share of loss / (profit) in JV / Associate, net	24	56	-57%	
PBT	787	246	220%	
Exceptional item	21	(271)	-	
PBT	808	(25)	-3269%	
Taxes	53	46	16%	
Taxes on exceptional item	2	(50)	-105%	
NET PROFIT BEFORE MINORITY INTEREST	753	(21)	-3739%	
Minority interest	90	60	49%	
Minority interest on exceptional item	3	(39)	-	
NET PROFIT FOR THE PERIOD	660	(42)	-1679%	
EPS Rs.	5.5	(0.3)		
NET PROFIT BEFORE EXCEPTIONAL ITEM				
	644	140	360%	
Exceptional item, net of taxes	16	(182)	-109%	
NET PROFIT FOR THE PERIOD	660	(42)	-1679%	
<i># Licensing Income</i>	5	11		
<i>* Gross Research & Development expenses</i>	332	365		

BIOCON LIMITED (CONSOLIDATED)			
PROFIT & LOSS STATEMENT			(Rs. Crores)
Particulars	Q3 FY 24	Q2 FY 24	Variance %
<u>INCOME</u>			
Generics	703	676	4%
Biosimilars	2,483	1,969	26%
Novel Biologics	-	-	0%
Research services	854	910	-6%
Inter-segment	(86)	(93)	-7%
Revenue from operations #	3,954	3,462	14%
Other income	565	158	258%
TOTAL REVENUE	4,519	3,620	25%
<u>EXPENDITURE</u>			
Material & Power costs	1,320	1,227	8%
Staff costs	555	530	5%
Research & Development expenses*	329	264	25%
Other expenses	823	700	18%
Manufacturing, staff & other expenses	3,027	2,721	11%
EBITDA	1,492	900	66%
Interest & Finance charges	267	248	8%
Depreciation & Amortisation	415	389	6%
Share of loss / (profit) in JV / Associate, net	24	24	0%
PBT BEFORE EXCEPTIONAL ITEM	787	238	230%
Exceptional item, Net	21	(24)	-100%
PBT	808	214	277%
Taxes	53	46	15%
Taxes on exceptional item	2	(4)	-155%
NET PROFIT BEFORE MINORITY INTEREST	753	173	336%
Minority interest	90	51	77%
Minority interest on exceptional item	3	(4)	-
NET PROFIT FOR THE PERIOD	660	126	425%
EPS Rs.	5.5	1.0	
RECONCILIATION OF NET PROFIT FOR THE PERIOD			
NET PROFIT BEFORE EXCEPTIONAL ITEM	644	142	355%
Exceptional item	16	(16)	
NET PROFIT FOR THE PERIOD	660	126	425%
<i># Licensing Income</i>	5	6	
<i>* Gross Research & Development expenses</i>	332	278	

BIOCON LIMITED (CONSOLIDATED)			
PROFIT & LOSS STATEMENT			(Rs. Crores)
Particulars	9M FY 24	9M FY 23	Variance %
<u>INCOME</u>			
Generics	2,080	2,020	3%
Biosimilars	6,466	3,481	86%
Novel Biologics	-	-	0%
Research services	2,572	2,199	17%
Inter-segment	(280)	(299)	-6%
Revenue from operations #	10,839	7,400	46%
Other income	817	221	270%
TOTAL REVENUE	11,656	7,621	53%
<u>EXPENDITURE</u>			
Material & Power costs	3,870	2,735	42%
Staff costs	1,605	1,475	9%
Research & Development expenses*	908	777	17%
Other expenses	2,073	898	131%
Manufacturing, staff & other expenses	8,456	5,886	44%
EBITDA	3,200	1,736	84%
Interest & Finance charges	747	171	338%
Depreciation & Amortisation	1,162	749	55%
Share of loss / (profit) in JV / Associate, net	82	127	100%
PBT BEFORE EXCEPTIONAL ITEM	1,209	689	75%
Exceptional item, Net	(3)	(288)	-
PBT	1,206	401	201%
Taxes	133	118	13%
Tax expense on adoption of new tax regime - exceptional	-	107	
Taxes on exceptional item	(2)	(53)	-100%
NET PROFIT BEFORE MINORITY INTEREST	1,075	229	370%
Minority interest	189	119	59%
Minority interest on exceptional item	(1)	(40)	-
NET PROFIT FOR THE PERIOD	887	150	493%
EPS Rs.	7.4	1.2	
NET PROFIT BEFORE EXCEPTIONAL ITEM			
Exceptional item, net of taxes	1	(196)	96%
Tax expense on adoption of new tax regime - exceptional	-	(107)	
NET PROFIT FOR THE PERIOD	887	150	493%
<i># Licensing Income</i>	178	31	
<i>* Gross Research & Development expenses</i>	934	839	

BIOCON LIMITED (CONSOLIDATED)
BALANCE SHEET

(Rs Crores)

Particulars	Dec 31, 2023	March 31, 2023
ASSETS		
Non-current assets		
(a) Property, plant and equipment	7,438	7,277
(b) Capital work-in-progress	3,982	2,588
(c) Right-of-use assets	482	258
(d) Goodwill	16,343	16,136
(e) Other intangible assets	6,434	5,796
(f) Intangible assets under development	3,827	4,730
(g) Investment in associates and a joint venture	2	138
(h) Financial assets		
Investments	664	605
Derivative assets	242	145
Other financial assets	209	1,083
(i) Income tax asset, net	462	354
(j) Deferred tax asset, net	270	301
(k) Other non-current assets	348	298
Non-current assets	40,703	39,709
Current assets		
(a) Inventories	5,023	4,244
(b) Financial assets		
Investments	1,927	1,327
Trade receivables	4,678	3,573
Cash and cash equivalents	1,024	1,324
Other bank balances	795	1,077
Derivative assets	186	70
Other financial assets	246	132
(c) Other current assets	949	588
Current assets	14,828	12,334
TOTAL - ASSETS	55,531	52,043

BIOCON LIMITED (CONSOLIDATED)
BALANCE SHEET

(Rs Crores)

Particulars	Dec 31, 2023	March 31, 2023
EQUITY AND LIABILITIES		
Equity		
(a) Equity share capital	600	600
(b) Other equity	19,142	17,267
Equity attributable to owners of the Company	19,742	17,867
Non-controlling interests	5,391	4,622
Total Equity	25,133	22,489
Non-current liabilities		
(a) Financial liabilities		
Borrowings	13,181	15,291
Lease liabilities	449	209
Derivative liabilities	127	26
Other financial liabilities	2,440	4,620
(b) Provisions	107	227
(c) Deferred tax liability, net	331	382
(d) Other non-current liabilities	326	290
Non-current liabilities	16,961	21,043
Current liabilities		
(a) Financial liabilities		
Borrowings	2,872	2,480
Lease liabilities	81	39
Trade payables	6,129	3,983
Derivative liabilities	18	59
Other financial liabilities	3,454	467
(b) Provisions	193	149
(c) Income tax liability, net	276	225
(d) Other current liabilities	414	1,109
Current liabilities	13,437	8,511
TOTAL - EQUITY AND LIABILITIES	55,531	52,043